Accumulating data suggest that tumors with rhabdoid features contain a clinicopathological spectrum of neoplasms with a highly variable rhabdoid cell component, with or without the loss of nuclear SMARCB1 expression. This evidence concerns the gene SMARCB1 and neoplasm.